The CJC-1295/Ipamorelin blend combines a GHRH analogue (CJC-1295) with a selective GHS-R agonist (Ipamorelin) to synergistically stimulate growth hormone release. Understanding the side effect profile of each component is essential for research safety. This review summarizes the adverse effects observed in available research for both components.
Research Use Only: This information is for educational and research purposes only. CJC-1295/Ipamorelin Blend is not FDA-approved for human use. Consult a qualified healthcare professional before any use.
CJC-1295 extends the half-life of GHRH signaling through DAC (Drug Affinity Complex) technology, while Ipamorelin selectively activates the ghrelin receptor (GHS-R1a) to stimulate GH release. Together, they produce synergistic GH pulses while minimizing cortisol and prolactin elevation compared to other GH secretagogues.
Mild redness, swelling, or discomfort at the injection site are the most commonly reported effects, consistent with subcutaneous peptide administration.
Mild fluid retention has been reported with CJC-1295 use, consistent with GH-mediated effects on sodium and water balance.
Mild headaches have been reported in research subjects, potentially related to GH-mediated effects on intracranial pressure.
Transient facial flushing has been reported, particularly with Ipamorelin administration, typically resolving within minutes.
Mild fatigue or lethargy has been reported in some research subjects, particularly during the initial period of administration.
Ipamorelin's ghrelin receptor agonism may increase appetite in some research subjects, consistent with ghrelin's orexigenic effects.
Peripheral numbness or tingling (paresthesia) has been reported with GH secretagogue use, potentially related to fluid retention effects on peripheral nerves.
Mild dizziness has been reported in some research subjects.
The CJC-1295/Ipamorelin blend is generally considered to have a favorable safety profile compared to exogenous GH administration, as it stimulates endogenous GH release within physiological feedback mechanisms. However, it is not FDA-approved for human use and should only be used in legitimate research settings. WADA prohibits both components for athletes.
The blend stimulates endogenous GH release within physiological feedback mechanisms, which is generally considered safer than exogenous HGH administration. However, it is not FDA-approved for human use.
Ipamorelin is specifically selected for its minimal effect on cortisol and prolactin compared to other GH secretagogues like GHRP-6. This selectivity is one of its key research advantages.
GH secretagogues can transiently affect insulin sensitivity. Research subjects with diabetes or insulin resistance should be monitored for glucose dysregulation.
Most reported side effects such as flushing, headache, and injection site reactions are transient and resolve within hours. Water retention may persist with ongoing administration.
Purgo Labs provides research-grade CJC-1295/Ipamorelin Blend with third-party HPLC and mass spectrometry verification from accredited US laboratories. Every batch ships with a full Certificate of Analysis.
Shop CJC-1295/Ipamorelin Blend at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.